1. Home
  2. LRE vs ELTX Comparison

LRE vs ELTX Comparison

Compare LRE & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

N/A

Current Price

$1.06

Market Cap

17.9M

Sector

N/A

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.00

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
ELTX
Founded
2001
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
63.3M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
LRE
ELTX
Price
$1.06
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
9.6K
328.1K
Earning Date
07-30-2015
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.71
52 Week High
$1.86
$16.00

Technical Indicators

Market Signals
Indicator
LRE
ELTX
Relative Strength Index (RSI) 22.83 28.75
Support Level N/A N/A
Resistance Level $1.33 $3.32
Average True Range (ATR) 0.03 0.14
MACD -0.02 -0.01
Stochastic Oscillator 17.74 26.37

Price Performance

Historical Comparison
LRE
ELTX

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: